Real-world Data Market (2026-2036)
The global real-world data market was valued at USD 1,326.6 million in 2026 and is projected to reach USD 2,493.0 million by 2036, growing at a CAGR of 6.5% during the forecast period 2026–2036.
- Published
- Apr 2026
- Pages
- 170
- Format
- PDF + Excel
- Report ID
- MRHC - 104611
- Base year
- 2025
- 2026 · ESTIMATED
- $1.33B
- 2036
- $2.49B
- CAGR 2026–2036
- 6.5%
2025 baseline · 2026–2036 forecast at 6.5% CAGR · hover a bar for the value
Key highlights
The global real-world data market is projected to reach USD 2, 493.0 million by 2036.
The market is expected to grow at a CAGR of 6.5% during the forecast period 2026–2036.
The global real-world data market is estimated at USD 1, 326.6 million in 2026.
North America is expected to dominate the global real-world data market throughout the forecast period, driven by the advanced healthcare infrastructure of the U.S. and Canada, a high concentration of RWD solution providers, and a progressive regulatory environment anchored by the FDA's Real-World Evidence Program and the 21st Century Cures Act.
Asia Pacific is projected to witness the fastest growth during the forecast period, propelled by healthcare digitization in China and India, expanding clinical trial activity, and evolving regulatory frameworks across Japan, South Korea, and Taiwan.
By source, the EMR/EHR/clinical data segment is expected to hold the largest share in 2026, driven by massive data volumes generated across hospital networks, accelerating adoption of interoperable EHR/EMR systems globally, and the widespread use of clinical data for real-world evidence generation in regulatory and commercial decision-making.
By source, the pharmacy data segment is projected to register the highest growth during the forecast period, driven by increasing demand for insights on medication utilization, treatment adherence, and real-world drug effectiveness.
By application, the market access and reimbursement/payer decisions segment is expected to account for the largest share in 2026.
By application, the drug development and approvals segment is expected to hold the second largest share of the global real-world data market in 2026.
By end user, the pharmaceutical, biotechnology, and medical device companies segment is expected to account for the largest share in 2026.
By geography, North America is expected to dominate the market in 2026, while Asia Pacific is expected to witness the fastest growth during the forecast period.
Report summary
| Particulars | Details |
|---|---|
| Market Size by 2036 | USD 2,493.0 Million |
| Market Size in 2026 | USD 1,326.6 Million |
| Revenue Growth Rate (2026–2036) | CAGR of 6.5% |
| Format | PDF, Excel & Cloud Portal · 170 pages |
| Dominating Source | EMR/EHR/Clinical Data |
| Fastest Growing Source | Pharmacy Data |
| Dominating Application | Market Access & Reimbursement/Payer Decisions |
| Fastest Growing Application | Drug Development & Approvals |
| Dominating End User | Pharmaceutical, Biotechnology & Medical Device Companies |
| Dominating Geography | North America |
| Fastest Growing Geography | Asia Pacific |
| Base Year | 2025 |
| Forecast Period | 2026 to 2036 |
Report overview
Segments covered: source, application, end user.
The global real-world data market covers healthcare data collected from a wide range of sources outside traditional randomized clinical trials. These sources include electronic health records and electronic medical records, which provide detailed information on patient diagnoses, treatments, laboratory results, medications, and clinical outcomes over time. Other key sources include medical claims and billing databases, pharmacy dispensing data, disease and product registries, genomics data, patient-generated health data from wearable devices and remote monitoring technologies, and unstructured clinical information such as physician notes, pathology reports, and medical images.
Together, these different types of data help generate real-world evidence that is now widely used across the pharma lifecycle from drug development and regulatory approvals to safety monitoring, health assessments, and everyday clinical decision making.
The growth of the overall real-world data market is primarily driven by the ongoing shift from traditional fee for service models toward value based care, which requires reliable data on patient outcomes and healthcare utilization. Rising drug development costs are also helping pharmaceutical companies to integrate real-world data across the product lifecycle, from early research through post market surveillance. At the same time, regulatory agencies are progressively recognizing the value of real-world evidence in supporting drug approvals, label expansions, and reimbursement decisions. Furthermore, the rapid growth of healthcare data, driven by prevalent adoption of electronic health records, connected medical devices, genomics technologies, and digital health platforms, is creating large datasets that can be analyzed to generate valuable clinical insights.
However, the growth of this market is restrained by strict data privacy regulations, limited data interoperability between healthcare systems, data quality concerns, and differences in regulatory requirements across regions. These challenges continue to pose barriers for organizations seeking to fully leverage real-world data for healthcare research and decision-making.
On the other hand, the integration of artificial intelligence and advanced analytics presents significant growth opportunities for market contributors by improving the ability to analyze large healthcare datasets and extract meaningful clinical insights. Emerging regulatory initiatives supporting data sharing and patient centric research are also expected to expand the use of real-world evidence substantially during the forecast period. Additionally, the growing focus on personalized medicine and the increasing clinical and commercial importance of underserved therapeutic areas are anticipated to further drive market growth.
A major trend shaping this market is the growing role of decentralized and patient centric data collection models, which are broadening the geographic and demographic reach of real-world evidence generation and supporting more representative analyses of treatment outcomes across diverse patient populations.
Report infographic
Market dynamics
5 factors across 3 forcesShift Toward Value-Based Care and Rising Drug Development Costs
A key driver of the real-world data market is the global healthcare industry's transition from volume-based to value-based care. In this paradigm, reimbursement is tied to patient outcomes and the overall value of care delivered. RWE is critical for all stakeholders to demonstrate and assess the real-world effectiveness and economic impact of a given therapy, enabling payers to make informed coverage decisions and providers to optimize treatment pathways. Concurrently, the biopharmaceutical industry is grappling with soaring R&D costs and lengthy development timelines. RWD offers a powerful solution to improve the efficiency of this process, from optimizing clinical trial design and recruitment to supporting regulatory submissions with supplementary evidence, thereby accelerating time-to-market and reducing costs.
Table of contents
11 chapters · 242 sections · 170 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Source | Large market share of this | Pharmacy data |
| By Application | Market access and reimbursement/payer decisions | — |
| Other segments | Drug development and approvals | — |
| By End User | Leading market share of this | — |
By Source
- The global real-world data market is segmented into EMR/EHR/clinical data, claims and billing data, pharmacy data, product/disease registries data, genomics data, patient-generated/wearable data, and other sources.
- The large market share of this segment is attributed to the massive volumes of structured and longitudinal data generated across hospital networks globally, the accelerating adoption of interoperable EHR and EMR systems, and the widespread use of clinical data for real-world evidence generation across regulatory and commercial decision-making contexts.
- However, the pharmacy data segment is projected to register the highest groth during the forecast period.
- The high growth of this segment is driven by increasing demand for insights related to medication utilization, treatment adherence, and real-world drug effectiveness.
- Pharmacy dispensing data provide detailed information on prescription fills, refill patterns, dosage adjustments, and medication persistence, which are critical for evaluating treatment outcomes and patient behavior in real-world settings.
- The growing focus on value based healthcare and outcomes-based reimbursement models is further driving demand for pharmacy data to assess the real-world performance of pharmaceutical products.
- The expansion of digital pharmacy platforms, specialty pharmacies, and integrated pharmacy benefit management systems is also improving data availability and enabling more comprehensive analysis of medication usage patterns.
By Application
- The global real-world data market is segmented into drug development and approvals, market access and reimbursement/payer decisions, post-market surveillance, medical device development and approvals, and clinical and regulatory decision-making.
- The large share of this segment is primarily because healthcare payers and insurance providers increasingly require real-world evidence to evaluate the clinical effectiveness, cost effectiveness, and long-term outcomes of therapies before granting coverage approvals.
- With the rising cost of innovative treatments, particularly in oncology, rare diseases, and advanced biologics, payers rely extensively on real-world data to support pricing negotiations, reimbursement decisions, and value-based payment models.
- Health technology assessment agencies and government healthcare programs similarly require evidence on treatment performance in real-world populations to ensure that healthcare spending delivers measurable patient outcomes.
- As a result, pharmaceutical companies frequently use real-world data to support payer submissions, coverage negotiations, and value-based contracts, which underpins the dominant market share of this segment.
Other segments
- The drug development and approvals segment is expected to account for the second largest share of the global real-world data market in 2026, driven by the accelerating integration of real-world evidence into pharmaceutical development pipelines, the expanding use of external control arms in regulatory submissions, and the growing recognition by the FDA and EMA of real-world evidence as a legitimate and increasingly required component of evidence packages for drug approvals and label expansions.
By End User
- The global real-world data market is segmented into pharmaceutical, biotechnology, and medical device companies; healthcare payers; healthcare providers; and other end users including academic research institutions, patient advocacy groups, government regulators, and health technology assessment agencies.
- The leading market share of this segment is driven by the growing adoption of real-world data across the drug development lifecycle, from target identification and clinical trial design through post-market surveillance, as well as the mounting regulatory and commercial imperative to demonstrate real-world treatment value to payers and health technology assessment bodies.
Geographic analysis
North America
Largest shareNorth America is projected to account for the largest share of the global real-world data market throughout the forecast period, driven by the advanced healthcare infrastructure of the United States and Canada, a high concentration of real-world data solution providers, and a progressive regulatory environment anchored by the FDA's Real-World Evidence Program and the 21st Century Cures Act.
Europe
Europe ranks as the second largest regional market and is experiencing a major shift in regulation and data governance with the launch of the European Health Data Space Regulation and the EU Joint Clinical Assessment framework in March 2025. These changes are expected to enhance cross border data access and speed up the use of real-world evidence in health technology assessments and reimbursement decisions across EU member states.
Asia-Pacific
Fastest growthHowever, Asia Pacific is expected to grow at the fastest rate during the forecast period. The rapid growth of this region is propelled by healthcare digitization in China and India, expanding clinical trial activity across the region, and evolving regulatory frameworks in Japan, South Korea, and Taiwan.
Latin America
Latin America and the Middle East and Africa, while relatively smaller markets, are growing as real-world data gains increasing traction in supporting health technology assessments and post-market surveillance programs.
Competitive landscape
- IQVIA Inc. (U.S.)
- PPD Inc. (U.S.)
- Merative (U.S.)
- Optum Inc. (U.S.)
- ICON plc · Ireland
- Syneos Health (U.S.)
- Aetion, Inc. (U.S.)
- Flatiron Health, Inc. (U.S.)
- Verana Health (U.S.)
- Oracle Corporation (U.S.)
- SAS Institute Inc. (U.S.)
- Parexel International Corporation (U.S.)
- Elevance Health, Inc. (U.S.)
Frequently asked questions
The global real-world data market is expected to reach USD 2,493.0 million by 2036 from an estimated USD 1,326.6 million in 2026, at a CAGR of 6.5% during the forecast period 2026–2036.
Cite this report
Meticulous Research. (2026). Real-world Data Market - Global Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MRHC - 104611). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/real-world-data-market-5297